SchizophreniaPhase 3NCT03345342
A Study of Paliperidone Palmitate 6-Month Formulation
A Phase 3 study testing PP6M, PP3M 350 mg eq. and PP3M 525 mg eq. in people with Schizophrenia, run by Janssen Research & Development, LLC at 138 sites in 21 countries.
Trial summary
The purpose of this study is to demonstrate that injection cycles consisting of a single administration of paliperidone palmitate 6-month (PP6M) are not less effective than 2 sequentially administered injections of paliperidone palmitate 3-month PP3M) (350 or 525 mg eq.) for the prevention of relapse in participants… Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Schizophrenia
- What is being tested?
- PP6M, PP3M 350 mg eq. and PP3M 525 mg eq.
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 841 participants
- Where
- 138 sitesin 21 countries
- Study dates
- 20 Nov 2017to 8 May 2020
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Must meet the diagnostic criteria for schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5) for at least 6 months before screening
- Must be receiving treatment with paliperidone palmitate (as either the paliperidone palmitate 1-month (PP1M) or paliperidone palmitate 3-month (PP3M) formulation), or injectable risperidone, or any oral antipsychotic
- Must be able, in the opinion of the investigator, to discontinue any antipsychotic medication other than PP1M) or PP3M during the Screening Phase
- Must have a full Positive and Negative Syndrome Scale (PANSS) score of less than (<) 70 points at screening
- Must have a body mass index (BMI) between 17 and 40 kilogram (kg)/meter (m)^2 (inclusive) and must have a body weight of at least 47 kg at screening
- Must be willing to receive gluteal injections of medication during the Double-blind Phase
Who cannot join
- Must not be receiving any form of involuntary treatment, such as involuntary psychiatric hospitalization, parole-mandated treatment, or court-mandated treatment
- Must not have attempted suicide within 12 months before screening and must not be at imminent risk of suicide or violent behavior, as clinically assessed by the investigator at the time of screening
- Must not have a DSM-5 diagnosis of moderate or severe substance use disorder (except for nicotine and caffeine) within 6 months of screening; however, acute or intermittent substance use prior to screening is not exclusionary, depending upon the clinical judgment of the investigator
- Must not have a history of neuroleptic malignant syndrome or tardive dyskinesia
- Must not have a history of intolerability or severe reactions to moderate or higher doses of antipsychotic medications and must not have any other factors that would, in the judgment of the investigator, indicate that treatment with moderate or higher doses of paliperidone palmitate would be intolerable or unsafe
Trial locations and contacts
138 sites in 21 countries.
138 sites in 21 countries
United States25 sites
California Pharmaceutical Research Institute, Inc.
Anaheim, California, 92804
Atlanta Center for Medical Research
Atlanta, Georgia, 30331
Massachusetts General Hospital
Boston, Massachusetts, 02114
Uptown Research Institute
Chicago, Illinois, 60640
Wexner Medical Center at the Ohio State University
Columbus, Ohio, 43210
ATP Clinical Research
Costa Mesa, California, 92626
Future Search Trials of Dallas
Dallas, Texas, 75231
Midwest Clinical Research Center
Dayton, Ohio, 45417
Collaborative NeuroScience Network
Garden Grove, California, 92845
The Zucker Hillside Hospital
Glen Oaks, New York, 11004
Cherry Street Services, Inc.
Grand Rapids, Michigan, 49503
New Life Medical Research Center, Inc.
Hialeah, Florida, 33012
Clinical Trials of America Inc
Hickory, North Carolina, 28601
Alexian Behavioral Health Hospital
Hoffman Estates, Illinois, 60169
Synergy East
Lemon Grove, California, 91945
Clintex Research Group
Miami, Florida, 33135
Florida Research Center Inc.
Miami, Florida, 33174
Pacific Research Partners
Oakland, California, 94607
University of Pennsylvania Medical Center
Philadelphia, Pennsylvania, 19104
Woodland Research Northwest
Rogers, Arkansas, 72758
Psychiatric and Behavioral Solutions
Salt Lake City, Utah, 84105-2425
SF-Care, Inc
San Rafael, California, 94901
St. Louis Clinical Trials
St Louis, Missouri, 63141
Olympian Clinical Research
Tampa, Florida, 33614
Ascension via Christi Research
Wichita, Kansas, 67214
Russia12 sites
Clinical Psychiatric Hospital #3 Named After V.A. Gilyarovsky
Moscow, 107076
Psychiatric Clinical hospital 1 named after N.A. Alekseev
Moscow, 117152
Nizny Novgorod clinical psychiatric hospital 1
Nizny Novgorod, 603155
Psychoneurological Dispensary of Frunzensky District
Saint Petersburg, 190013
Psychoneurological dispensary 10
Saint Petersburg, 190121
St-Petersburg Bekhterev Psychoneurological Research Institute
Saint Petersburg, 192109
Psychoneurological dispensary 1
Saint Petersburg, 199178
SHI 'Saratov City Clinical Hospital 2 n.a V.I. Razumovsky
Saratov, 410028
Saratov Regional Psychiatric hospital named after St. Sofia
Saratov, 410060
Psychoneurological Dispensary #4
St.Peterburg, 197110
Research Institute of Mental Health
Tomsk, 634014
Sverdlovsk Regional Clinical Psychiatric Hospital
Yekaterinburg
Poland10 sites
Mlynowamed Specjalistyczny Psychiatryczny Gabinet Lekarski Joanna Lazarczyk
Bialystok, 15-404
Wlokiennicza MED Specjalistyczna Praktyka Lekarska dr n.med. Tomasz Markowski
Bialystok, 15-464
Zespol Opieki Zdrowotnej w Chelmnie
Chełmno, 86-200
Centrum Badan Klinicznych PI House sp z o o
Gdansk, 80 546
Szpital Specjalistyczny im H Klimontowicza Oddzial Psychiatryczny
Gorlice, 38-300
Niepubliczny Zaklad Opieki Psychiatrycznej MENTIS
Leszno, 64-100
Centrum Medyczne Luxmed Sp z o o
Lublin, 20 109
Poradnia Zdrowia Psychicznego 'Syntonia' w Pruszczu Gdanskim
Pruszcz Gdański, 83-000
Mazowieckie Specjalistyczne Centrum Zdrowia im. Prof. Jana Mazurkiewicza w Pruszkowie
Pruszków, 05-802
Wojewodzki Szpital Zespolony im L Rydygiera w Toruniu
Torun, 87 100
Ukraine9 sites
MNCE of Kyiv RC Regional Psychiatric and Narcological Medical Association
Hlevakha, 8630
Mnpe of Kharkiv Regional Council 'Regional Clinical Psychiatric Hospital #3'
Kharkiv, 61068
CNPE'Kherson Regional Institution of Mental Care'of Kherson Regional Council
Kherson, 73488
Kyiv Territorial Medical Incorporation 'Psychiatry'
Kyiv, 04080
Municipal Institution 'Lviv Regional Clinical Psycho-Neurological Dispensary'
Lviv, 79017
CNCE of the Lviv Regional Council 'Lviv Regional Clinical Psychiatric Hospital'
Lviv, 79021
CNCE Odesa regional psychiatric hospital #2 Odesa regional council
Oleksandrivka, 67513
CNCE 'Cherkasy Regional Psychiatric Hospital of Cherkasy Regional Council'
Smila, 20708
CNCE 'Vinnytsya RC Psychoneurological Hospital n.a. O.I. Yushchenko Vinnytsya RC'
Vinnytsia, 21005
India8 sites
Ratandeep Multispeciality Hospital
Ahmedabad, 380008
Sri Ramachandra Medical Centre
Chennai, 600116
Asha hospital
Hyderabad, 500034
Ahana Hospitals
Madurai, 625020
Vinaya Hospital and Research Center
Mangalore, 575003
Kasturba Medical College Hospital
Manipal, 576104
Jehangir Clinical Development Center Pvt Ltd
Pune, 411001
Deva Institute of Health Care and Research Pvt Ltd
Varanasi, 221005
Brazil7 sites
Trial Tech Tecnologia em Pesquisas com Medicamentos
Curitiba, 80240-280
Instituto Bairral de Psiquiatria
Itapira, 13970-905
Hospital das Clinicas de Porto Alegre
Porto Alegre, 90035-903
Ruschel Medicina e Pesquisa Clínica Ltda
Rio de Janeiro, 22270 060
CPQuali Pesquisa Clinica LTDA ME
São Paulo, 01228-900
SPDM - Associacao Paulista para o Desenvolvimento da Medicina - Hospital Sao Paulo
São Paulo, 04020-060
Hospital Das Clinicas Da Faculdade De Medicina Da USP
São Paulo, 05403-903
Spain7 sites
Hosp Univ Vall D Hebron
Barcelona, 08035
Inst. Internac. Neurociencias Aplicadas
Barcelona, 8006
Hosp. Univ. de Basurto
Bilbao, 48013
Centro Salud Mental La Corredoria
Oviedo, 33011
Hosp. El Bierzo
Ponferrada, 24404
Hosp. Clinico Univ. de Valencia
Valencia, 46010
Hosp. Prov. de Zamora
Zamora, 49021
Argentina6 sites
Fundacion para el Estudio y Tratamiento de las Enfermedades Mentales
Buenos Aires, C1133AAH
CEN
Córdoba, X5004FJF
Sanatorio Prof. Leon S. Morra
Córdoba, X5009BIN
Instituto de Neurociencias San Agustin
La Plata, 1900
Clinica Privada de Salud Mental Santa Teresa de Ávila
La Plata, B1904ADM
C I A P Centro de investigacion y Asistencia en Psiquiatria
Rosario, 2000
Bulgaria6 sites
Mental Health Center Prof. Dr. Ivan Temkov
Burgas, 8001
State Psychiatric Hospital Pazardzhik
Pazardzhik, 4400
UMHAT 'Sveti Georgi'-Plovdiv
Plovdiv, 4002
State Psychiatric HospitalDr.Georgi Kissiov
Radnevo, 6260
Centre for Mental Health Prof.N.Shipkovenski EOOD
Sofia, 1377
Medical Center Intermedica, OOD
Sofia, 1680
Czechia6 sites
Psychiatricka ambulance, MUDr. Marta Holanova
Brno, 61500
NeuropsychiatrieHK, s.r.o.
Hradec Kralove-Vekose, 50341
A Shine S R O
Pilsen, 31200
Pragtis S R O
Prague, 12000
Institut Neuropsychiatricke pece
Prague, 18600
Psychiatricka ambulance MUDr. Simona Papezova
Prague, 19000
France5 sites
C.H.S. Charles Perrens
Bordeaux, 33076
CHRU La Colombière
Montpellier, 34090
CHU Caremeau
Nîmes, 30029
Hopital Sainte Anne
Paris, 75674
Hopital Sainte Musse
Toulon, 83000
Mexico5 sites
Gabipros SC
Mexico City, 07810
Instituto Neuropsique
Monterrey, 64610
Centro de Estudios Clinicos y Especialidades Medicas S C
Monterrey, 64620
Infosame/Research
Monterrey, 64710
Centro de Atencion e Investigacion Cardiovascular del Potosi S C
San Luis Potosí City, 78200
Turkey (Türkiye)5 sites
Abdurrah Yurtarslan Training and Research Hospital
Ankara, 6200
Ankara Numune Research and Training Hospital
Ankara, 6800
Erenkoy Mental Health Hospital
Istanbul, 34736
Selcuk University, Medical School, Department of Psychiatry
Konya, 42130
Sakarya University Medical Faculty Psychiatry Department
Sakarya, 54187
Hungary4 sites
Józsefvarosi Szent Kozma Egészségügyi Központ
Budapest, 1084
Petz Aladar Megyei Oktato Korhaz
Győr, 9023
Bács-Kiskun Megyei Kórház a Szegedi Tudományegyetem Általános Orvostudományi Kar Oktató Kórháza
Kalocsa, 6300
CRU Hungary Kft.
Miskolc, 3529
Italy4 sites
Clinica Psichiatrica - Università di Cagliari
Cagliari, 09127
Dipartimento di Salute Mentale
Lecce, 73100
Seconda Universita degli Studi di Napoli - Azienda Ospedaliera Universitaria
Naples, 80138
Universita degli Studi di Roma 'La Sapienza' - Azienda Ospedaliera Sant Andrea
Roma, 00189
Malaysia4 sites
Hospital Bahagia Ulu Kinta
Ipoh, 31250
Hospital Kuala Lumpur
Kuala Lumpur, 50586
University Malaya Medical Centre
Kuala Lumpur, 59100
Sarawak General Hospital
Kuching, 93586
South Korea4 sites
Chonnam National University Hospital
Gwangju, 61469
CHA Bundang Medical Center, CHA University
Gyeonggi-do, 13496
Chonbuk National Univ Hospital
Jeonju, 54907
Seoul National University Hospital
Seoul, 03080
Taiwan4 sites
National Cheng Kung University Hospital
Tainan, 70403
Mackay Memorial Hospital
Taipei, 10449
Taipei Veterans General Hospital
Taipei, 11217
Chang Gung Memorial Hospital
Taoyuan, 333
South Africa3 sites
Flexivest 14 Research
Cape Town, 7550
Gert Bosch Pretoria South Africa
Pretoria, 0042
Juan Schrönen - Western Cape South Africa
Welgemoed, 7530
Australia2 sites
The Lyell McEwin Hospital
Elizabeth Vale, 5112
Neuro Trials Victoria
Noble Park, 3174
About this study
Official title: A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation
The purpose of this study is to demonstrate that injection cycles consisting of a single administration of paliperidone palmitate 6-month (PP6M) are not less effective than 2 sequentially administered injections of paliperidone palmitate 3-month PP3M) (350 or 525 mg eq.) for the prevention of relapse in participants with schizophrenia previously stabilized on corresponding doses of paliperidone palmitate 1-month (PP1M) (100 or 150 mg eq.) or PP3M (350 or 525 mg eq.).
Read the detailed description
The primary hypothesis of this study is that the efficacy of PP6M is non-inferior to PP3M for preventing relapse in participants with schizophrenia who were previously stabilized on corresponding doses of PP1M or PP3M. The study consists of mainly 3 phases: a screening phase (up to 28 days), a maintenance phase (of 1 or 3 months), and a double-blind phase (of 12 months [neither the researchers nor the participants know what treatment the participant is receiving]). Additional/conditional phases include a transition phase (before maintenance phase). Study evaluations include efficacy, pharmacokinetics, pharmacodynamics, and safety. The study duration will vary from approximately 13 months to 19 months.
- Conditions
- Schizophrenia
- Being tested
- PP6M, PP3M 350 mg eq., PP3M 525 mg eq., PP1M, Placebo
- Medical subject headings
- Schizophrenia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PP6MDrug
Also called R092670
Participants will receive intramuscular injection of PP6M.
PP3M 350 mg eq.Drug
Also called R092670
Participants will receive intramuscular injection of PP3M 350 mg eq.
PP3M 525 mg eq.Drug
Also called R092670
Participants will receive intramuscular injection of PP3M 525 mg eq.
PP1MDrug
Also called R092670
Participants will receive intramuscular injection of PP1M 50 to 150 mg eq.
PlaceboOther
Participants will receive matching placebo.
| Study group | Role | What they receive |
|---|---|---|
| PP1M: Transition Phase | Experimental | Participants who previously have not achieved stability with moderate to higher doses of Paliperidone palmitate 1-month (PP1M) or Paliperidone palmitate 3-month (PP3M) will enter into a transition period of up to 4 months. During transition period participants will receive 1 to 5 injections of PP1M 50 to 100 milligrams equivalent (mg eq.). The participants who achieved stability (stability is defined as at least 3 months of injections with the last 2 doses being the same strength) with PP1M 100 mg eq. will precede from transition phase to maintenance phase. Receives: Drug: PP1M |
| PP1M/PP3M: Maintenance Phase | Experimental | All the participants will receive only 1 dose of PP1M 100 or 150 mg eq. or PP3M 350 or 525 mg eq. The participants will precede from maintenance phase to double-blind phase. Receives: Drug: PP3M 350 mg eq.; Drug: PP3M 525 mg eq.; Drug: PP1M |
| PP6M or Placebo: Double-Blind Phase | Experimental | Participants will receive intramuscular injection of PP6M in left gluteal muscle on Day 1 and right gluteal muscle on Day 183 with alternating placebo in right gluteal muscle on Day 92 and left gluteal muscle on Day 274. Receives: Drug: PP6M; Other: Placebo |
| PP3M: Double-Blind Phase | Experimental | Participants will receive intramuscular injections of PP3M at dose of 350 mg eq. or 525 mg eq. in left gluteal muscle on Day 1 and 274 and right gluteal muscle on Day 92 and 183. Receives: Drug: PP3M 350 mg eq.; Drug: PP3M 525 mg eq. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to Relapse During the Double-Blind (DB) Phase
Time to relapse is time between participant randomization in DB Phase and first documentation of relapse event by end of Month 12 of DB phase. Relapse is defined as: a) Psychiatric hospitalization; b) Positive and Negative Syndrome Scale (PANSS) total score: Increase of 25 percentage (%), 10 point increase in PANSS for 2 analysis separated by 3-7 days if score was greater than (>) 40, less than or equal to (<=)40; c) Participants inflicted knowing self-injury/shown violent behavior leading to suicide, clinically significant injury to him/herself or other person/property; d) Participants had suicidal/homicidal ideation/violent behavior that was clinically significant as per investigator; e) PANSS items P1- delusions, P2- conceptual disorganization, P3-hallucinatory behavior, P6- suspiciousness/ persecution, P7-hostility, G8-uncooperativeness: score: greater than or equal to (>=)5, >=6 for 2 analysis separated by 3-7 days on any items if maximum score for PANSS: <=3 or 4, respectively.
Measured: Up to 12 months of DB Phase
Secondary outcomes (19)
Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score
The neuropsychiatric symptoms of schizophrenia were assessed using the 30-item PANSS scale, which provides a total score (sum of the scores for all 30 items) and scores for 3 subscales: the 7-item positive-symptom (P) subscale, the 7-item negative-symptom (N) subscale, and the 16-item general-psychopathology symptom (G) subscale. Each item is rated on a scale from 1 (absent) to 7 (extreme). The PANSS total score ranges from 30 (absent disease)-210 (more severe neuropsychiatric symptoms of schizophrenia).
Measured: Baseline (DB) to 12 Months of DB Phase
Change From Baseline in the Clinical Global Impression - Severity (CGI-S) Score
CGI-S is defined as clinician-rated scale that assesses the severity of mental illness on a scale of 0 to 7. Considering total clinical experience, a participant was assessed on severity of mental illness at the time of rating according to:1: normal, not at all ill; 2: borderline mentally ill; 3: mildly ill; 4: moderately ill; 5: markedly ill; 6: severely ill; 7: among the most extremely ill patients. A higher score implies a more severe condition.
Measured: Baseline (DB) to 12 Months of DB Phase
Change From Baseline in the Personal and Social Performance (PSP) Scale Total Score
The Personal and Social Performance (PSP) scale assesses degree of a participant's dysfunction within 4 domains of behavior: 1) socially useful activities, 2) personal and social relationships, 3) self-care, and 4) disturbing and aggressive behavior. Each domain was assessed on a 6-point scale, from 1 (absent) to 6 (very severe) (1 = absent, 2 = mild, 3 = manifest, 4 = marked, 5 = severe, and 6 = very severe). PSP total score was calculated as sum of all the domain scores and ranges from 1 to 100. Participants with score of 71 to 100 have mild degree of difficulty; from 31 to 70, varying degrees of disability; less than or equal to 30, functioning so poorly as to require intensive supervision. Higher score indicates better performance.
Measured: Baseline (DB) to 12 Months of DB Phase
Percentage of Participants With Symptomatic Remission Based on PANSS Score During DB Phase
Symptomatic remission was defined as achieving intensity level of mild or moderate on PANSS scale by all 8 items as the determinants for symptomatic remission: delusions, unusual thought content, hallucinatory behavior, conceptual disorganization, mannerisms/posturing, blunted affect, social withdrawal, lack of spontaneity. The PANSS is a 30-item scale to assess the neuropsychiatric symptoms of schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self). The PANSS provides a total score and scores for 3 subscales, the positive subscale (7 items), the negative subscale (7 items), and the general psychopathology subscale (16 items), each item scored on a scale of 1 (absent), 2 (minimal), 3 (mild), 4 (moderate), 5 (moderately severe), 6 (severe) and 7 (extreme). The total score ranges from 30 to 210 and higher score indicates greater severity.
Measured: Up to 12 months of DB Phase
Change From Baseline in the Satisfaction With Participants in Social Roles (SPSR) Score
The SPSR Short Form 8a is a participant-reported outcome used to assess the satisfaction with participation in social roles. The participants were asked to rate 8 items on 5-point Likert scale, with scores ranging from 8 to 40, where higher scores represents higher satisfaction.
Measured: Baseline (DB) to 12 Months of DB Phase
Change From Baseline in the Treatment Satisfaction Questionnaire for Medication (TSQM-9) Total Score
TSQM-9 consists of 9 questions to assess patients' satisfaction with medication using a range of responses from 1 (extremely dissatisfied) to (7 extremely satisfied). This patient reported outcome provides scores on three parts: effectiveness, convenience, and global satisfaction. The sum of the 9-questions were calculated and used for analysis. The total score ranges from 0 to 63, with higher scores indicating better treatment satisfaction.
Measured: Baseline (DB) to 12 Months of DB Phase
Change From Baseline in the Simpson-Angus Rating Scale (SAS) Total Score
The SAS rates 10 items for general extrapyramidal symptoms (EPS) on a 5-point scale from 0 (normal) to 4 (extreme), including gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, leg pendulousness, head rotation, Glabellar tap, tremor, and salivation. The SAS total score is the average score (total sum of item scores divided by the number of items) and ranges between 0 and 4. Negative change in score indicates improvement. Higher scores denote more severe condition of EPS.
Measured: Baseline (DB) to 12 Months of DB Phase
Number of Participants With Symptoms of Akathisia Assessed Using Barnes Akathisia Rating Scale (BARS) Score
BARS is used to rate observable, restless movements of drug induced akathisia and subjective awareness of restlessness and any distress associated with the akathisia. BARS consists of the following 4 items: objective assessment of akathisia symptoms, subjective assessment of the participants's awareness of inner restlessness, distress restlessness, and global clinical assessment of akathisia. First three items are rated on a 4-point scale ranging from 0 (no abnormal movements or absence of inner restlessness or no distress) to 3 (severe akathisia or awareness of intense compulsion to move most of the time or severe distress). The last item, the global clinical assessment of akathisia, is rated on a 6-point scale, ranging from 0 (no evidence of akathisia) to 5 (severe akathisia).
Measured: Up to 12 Months of DB Phase
Change From Baseline in the Abnormal Involuntary Movement Scale (AIMS) Total Score
AIMS is a 14-item scale. Items 1 to 8 are rated on a 5-point scale ranging from 0 (no dyskinetic movements) to 4 (severe dyskinetic movements). Item 9 assesses the participant's incapacitation due to abnormal movements, and item 10 assesses the participant's awareness of the abnormal movements and associated distress. Items 9 and 10 are rated on 5-point scales ranging from 0 (none or no awareness) to 4 (severe or aware, severe distress). Items 11 to 14 are yes/no questions regarding the global judgement and dental status of the participant. The total score is the sum of the scores for the 14 items and the possible total score ranges from 0 to 44. A higher total score is indicative of more severe dyskinetic movements.
Measured: Baseline (DB) to 12 Months of DB Phase
Number of Participants Based on Columbia Suicide Severity Rating Scale (C-SSRS) Total Score
The C-SSRS is a questionnaire used for suicide risk assessment. Affirmative or negative responses are provided to items 1 to 5 for suicidal ideation (1. Wish to be dead, 2. Non-specific active suicidal thoughts, 3. Active suicidal ideation with any methods [not plan] without intent to act, 4. Active suicidal ideation with some intent to act, without specific plan, 5. Active suicidal ideation with specific plan and intent) and items 6 to 10 for suicide behavior (6. Preparatory acts or behavior, 7. Aborted attempt, 8. Interrupted attempt, 9. Actual attempt, 10. Completed suicide). Total score ranges from 1 to 10. Higher scores indicate more severe suicidal ideation.
Measured: Baseline and endpoint (12 Months of DB Phase)
Number of Participants With Treatment-emergent Abnormal Electrocardiogram (ECG) Values During DB Phase
Number of participants with treatment-emergent abnormal ECG values were reported. It includes heart rate (abnormally low refers to less than or equal to [<=] 50 beats per minute (bpm) , abnormally high refers greater than or equal to [>=] 100 bpm), pulse rate (PR) interval (abnormally high refers to >= 210 milliseconds [msec]), QRS interval (abnormally Low refers to <= 50, abnormally high refers to >= 120 msec) and QT interval (abnormally low refers to <= 200, abnormally high >= 500 msec).
Measured: Baseline (DB) to 12 Months of DB Phase
Change From Baseline in the Body Mass Index (BMI) During DB Phase
Change from baseline in BMI was reported.
Measured: Baseline (DB) to 12 Months of DB Phase
Change From Baseline in the Waist Circumference During DB Phase
Change from baseline in waist circumference was reported.
Measured: Baseline (DB) to 12 Months of DB Phase
Change From Baseline in the Body Weight During DB Phase
Change from baseline in body weight was reported.
Measured: Baseline (DB) to 12 Months of DB Phase
Change From Baseline in the Vital Signs (Pulse Rate) During DB Phase
Change from baseline vital signs (pulse rate) were reported. This included supine pulse rate, standing pulse rate and supine-standing pulse rate.
Measured: Baseline (DB) to 12 Months of DB Phase
Change From Baseline in the Vital Signs (Systolic Blood Pressure [SBP] and Diastolic Blood Pressure [DBP]) During DB Phase
Change from baseline in vital signs including SBP and DBP (supine/standing) were reported.
Measured: Baseline (DB) to 12 Months of DB Phase
Change From Baseline in Positive and Syndrome Scale (PANSS) Subscales Score During DB Phase
The neuropsychiatric symptoms of schizophrenia were assessed using the 30-item PANSS scale, which provides a total score (sum of the scores for all 30 items) and Scores for 3 subscales, that is, for positive subscale (sum of the scores of all 7 items) and negative subscale (sum of the scores of all 7 items) ranges from 7 (absent) to 49 (extreme psychopathology), and for the general psychopathology subscale (sum of the scores of all 16 items) score ranges from 16 (absent) to 112 (extreme psychopathology).
Measured: Baseline (DB) to 12 Months of DB Phase
Number of Participants With Treatment-emergent Clinically Significant Abnormal Laboratory Values in Chemistry During DB Phase
Number of participants with clinically significant abnormal laboratory values in chemistry included alanine aminotransferase (Unit per Litre [U/L]), albumin (Gram per Litre [g/L]), alkaline phosphatase (U/L), aspartate aminotransferase (U/L), bicarbonate (millimoles per litre [mmol/L]), bilirubin (micromoles per litre [umol/L]), calcium (mmol/L), chloride (mmol/L), cholesterol (mmol/L), creatinine (umol/L), gamma glutamyl transferase (GGT) (U/L), glucose (mmol/L), high-density lipoproteins (HDL) cholesterol (mmol/L), low density lipoproteins (LDL) cholesterol (mmol/L), lactate dehydrogenase (U/L), phosphate (mmol/L), potassium (mmol/L), protein (mmol/L), sodium (mmol/L), triglycerides (mmol/L), urate (umol/L), urea nitrogen (mmol/L) were reported. Here, ABL signifies abnormally low and ABH signifies abnormally high levels.
Measured: Up to 12 Months of DB Phase
Number of Participants With Treatment-emergent Clinically Significant Abnormal Laboratory Values in Hematology During DB Phase
Number of participants with clinically significant abnormal laboratory values in hematology included hemoglobin (Hb), hematocrit (Hct), red blood cell (RBC) count, white blood cell (WBC) count with differential, platelets, hemoglobin A1c. Here, ABL signifies abnormally low and ABH signifies abnormally high levels.
Measured: Up to 12 Months of DB Phase
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Nov 2017
- Study start20 Nov 2017
- Primary completion8 May 2020
- Study completion8 May 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for SchizophreniaStudies of the same condition, open and under way.
- More trials run by Janssen Research & Development, LLCThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 841 participants (actual)
Sponsor and investigators
- Lead sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Janssen Research & Development, LLC Clinical Trial, Study director, Janssen Research & Development, LLC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03345342
- Sponsor's protocol ID
- CR108390
- Other IDs
- R092670PSY3015, 2017-001941-28, 2017
- Status last verified
- Apr 2025
- First submitted
- 14 Nov 2017
- Last updated
- 29 Apr 2025
- Results posted
- Yes, on ClinicalTrials.gov
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Publications
Guirguis M, Knight RK, Sanga P, Han J, Galderisi S. Weight and metabolic changes in patients with schizophrenia treated with paliperidone palmitate 6-month formulation versus paliperidone palmitate 3-month formulation: a post-hoc analysis. Int J Neuropsychopharmacol. 2026 Sep 1;29(9):pyag042. doi: 10.1093/ijnp/pyag042.
PubMed 42623271Correll CU, Johnston KL, Turkoz I, Kutch M, Knight RK, Doring M, Sajatovic M. Comparing two transitioning strategies to paliperidone palmitate once-every-6-months. CNS Spectr. 2024 Dec;29(6):633-639. doi: 10.1017/S1092852924000476. Epub 2024 Nov 8.
PubMed 39511777Richarz U, Han J, Bai YM, Yu-Hai Chen E, Chung YC, Jhanwar VG, Kim SW, Sulaiman AH, Knight K, Gopal S. Efficacy and safety of paliperidone palmitate 6-monthly long-acting injectable in reduction of relapses in patients with schizophrenia: An Asian subgroup analysis of phase 3, randomized study. Medicine (Baltimore). 2023 Aug 25;102(34):e34623. doi: 10.1097/MD.0000000000034623.
PubMed 37653768Najarian D, Turkoz I, Knight RK, Galderisi S, Lamaison HF, Zalitacz P, Aravind S, Richarz U. Long-Term Efficacy and Safety of Paliperidone 6-Month Formulation: An Open-Label 2-Year Extension of a 1-Year Double-Blind Study in Adult Participants With Schizophrenia. Int J Neuropsychopharmacol. 2023 Aug 29;26(8):537-544. doi: 10.1093/ijnp/pyad028.
PubMed 37480362Najarian D, Sanga P, Wang S, Lim P, Singh A, Robertson MJ, Cohen K, Schotte A, Milz R, Venkatasubramanian R, T'Jollyn H, Walling DP, Galderisi S, Gopal S. A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia. Int J Neuropsychopharmacol. 2022 Mar 17;25(3):238-251. doi: 10.1093/ijnp/pyab071.
PubMed 34791283
Study at a glance
From the registry record, last updated by the sponsor on 29 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation
- ClinicalTrials.gov ID
- NCT03345342
- Acronym / sponsor ID
- CR108390
- Conditions
- Schizophrenia
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 841 participants (actual)
- Lead sponsor
- Janssen Research & Development, LLCIndustry (pharma, biotech, devices)
- Study start
- 20 Nov 2017 (actual)
- Primary completion
- 8 May 2020 (actual)
- Study completion
- 8 May 2020 (actual)
- First posted
- 17 Nov 2017 (actual)
- Results
- Posted 9 Dec 2021
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to demonstrate that injection cycles consisting of a single administration of paliperidone palmitate 6-month (PP6M) are not less effective than 2 sequentially administered injections of paliperidone palmitate 3-month PP3M) (350 or 525 mg eq.) for the prevention of relapse in participants with schizophrenia previously stabilized on corresponding doses of paliperidone palmitate 1-month (PP1M) (100 or 150 mg eq.) or PP3M (350 or 525 mg eq.).
Detailed description
The primary hypothesis of this study is that the efficacy of PP6M is non-inferior to PP3M for preventing relapse in participants with schizophrenia who were previously stabilized on corresponding doses of PP1M or PP3M. The study consists of mainly 3 phases: a screening phase (up to 28 days), a maintenance phase (of 1 or 3 months), and a double-blind phase (of 12 months [neither the researchers nor the participants know what treatment the participant is receiving]). Additional/conditional phases include a transition phase (before maintenance phase). Study evaluations include efficacy, pharmacokinetics, pharmacodynamics, and safety. The study duration will vary from approximately 13 months to 19 months.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| PP1M: Transition Phase | Experimental | Drug: PP1MParticipants who previously have not achieved stability with moderate to higher doses of Paliperidone palmitate 1-month (PP1M) or Paliperidone palmitate 3-month (PP3M) will enter into a transition period of up to 4 months. During transition period participants will receive 1 to 5 injections of PP1M 50 to 100 milligrams equivalent (mg eq.). The participants who achieved stability (stability is defined as at least 3 months of injections with the last 2 doses being the same strength) with PP1M 100 mg eq. will precede from transition phase to maintenance phase. |
| PP1M/PP3M: Maintenance Phase | Experimental | Drug: PP3M 350 mg eq., Drug: PP3M 525 mg eq., Drug: PP1MAll the participants will receive only 1 dose of PP1M 100 or 150 mg eq. or PP3M 350 or 525 mg eq. The participants will precede from maintenance phase to double-blind phase. |
| PP6M or Placebo: Double-Blind Phase | Experimental | Drug: PP6M, Other: PlaceboParticipants will receive intramuscular injection of PP6M in left gluteal muscle on Day 1 and right gluteal muscle on Day 183 with alternating placebo in right gluteal muscle on Day 92 and left gluteal muscle on Day 274. |
| PP3M: Double-Blind Phase | Experimental | Drug: PP3M 350 mg eq., Drug: PP3M 525 mg eq.Participants will receive intramuscular injections of PP3M at dose of 350 mg eq. or 525 mg eq. in left gluteal muscle on Day 1 and 274 and right gluteal muscle on Day 92 and 183. |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Must meet the diagnostic criteria for schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5) for at least 6 months before screening
- Must be receiving treatment with paliperidone palmitate (as either the paliperidone palmitate 1-month (PP1M) or paliperidone palmitate 3-month (PP3M) formulation), or injectable risperidone, or any oral antipsychotic
- Must be able, in the opinion of the investigator, to discontinue any antipsychotic medication other than PP1M) or PP3M during the Screening Phase
- Must have a full Positive and Negative Syndrome Scale (PANSS) score of less than (<) 70 points at screening
- Must have a body mass index (BMI) between 17 and 40 kilogram (kg)/meter (m)^2 (inclusive) and must have a body weight of at least 47 kg at screening
Key exclusion criteria (5 listed)
- Must not be receiving any form of involuntary treatment, such as involuntary psychiatric hospitalization, parole-mandated treatment, or court-mandated treatment
- Must not have attempted suicide within 12 months before screening and must not be at imminent risk of suicide or violent behavior, as clinically assessed by the investigator at the time of screening
- Must not have a DSM-5 diagnosis of moderate or severe substance use disorder (except for nicotine and caffeine) within 6 months of screening; however, acute or intermittent substance use prior to screening is not exclusionary, depending upon the clinical judgment of the investigator
- Must not have a history of neuroleptic malignant syndrome or tardive dyskinesia
- Must not have a history of intolerability or severe reactions to moderate or higher doses of antipsychotic medications and must not have any other factors that would, in the judgment of the investigator, indicate that treatment with moderate or higher doses of paliperidone palmitate would be intolerable or unsafe
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PP6MAlso: R092670Participants will receive intramuscular injection of PP6M. | Drug | PP6M or Placebo: Double-Blind Phase |
| PP3M 350 mg eq.Also: R092670Participants will receive intramuscular injection of PP3M 350 mg eq. | Drug | PP1M/PP3M: Maintenance Phase, PP3M: Double-Blind Phase |
| PP3M 525 mg eq.Also: R092670Participants will receive intramuscular injection of PP3M 525 mg eq. | Drug | PP1M/PP3M: Maintenance Phase, PP3M: Double-Blind Phase |
| PP1MAlso: R092670Participants will receive intramuscular injection of PP1M 50 to 150 mg eq. | Drug | PP1M/PP3M: Maintenance Phase, PP1M: Transition Phase |
| PlaceboParticipants will receive matching placebo. | Other | PP6M or Placebo: Double-Blind Phase |
Primary outcome
Time to Relapse During the Double-Blind (DB) Phase
Time frame: Up to 12 months of DB Phase
Time to relapse is time between participant randomization in DB Phase and first documentation of relapse event by end of Month 12 of DB phase. Relapse is defined as: a) Psychiatric hospitalization; b) Positive and Negative Syndrome Scale (PANSS) total score: Increase of 25 percentage (%), 10 point increase in PANSS for 2 analysis separated by 3-7 days if score was greater than (>) 40, less than or equal to (<=)40; c) Participants inflicted knowing self-injury/shown violent behavior leading to suicide, clinically significant injury to him/herself or other person/property; d) Participants had suicidal/homicidal ideation/violent behavior that was clinically significant as per investigator; e) PANSS items P1- delusions, P2- conceptual disorganization, P3-hallucinatory behavior, P6- suspiciousness/ persecution, P7-hostility, G8-uncooperativeness: score: greater than or equal to (>=)5, >=6 for 2 analysis separated by 3-7 days on any items if maximum score for PANSS: <=3 or 4, respectively.
19 secondary outcomes
Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score
Time frame: Baseline (DB) to 12 Months of DB Phase
Change From Baseline in the Clinical Global Impression - Severity (CGI-S) Score
Time frame: Baseline (DB) to 12 Months of DB Phase
Change From Baseline in the Personal and Social Performance (PSP) Scale Total Score
Time frame: Baseline (DB) to 12 Months of DB Phase
Percentage of Participants With Symptomatic Remission Based on PANSS Score During DB Phase
Time frame: Up to 12 months of DB Phase
Change From Baseline in the Satisfaction With Participants in Social Roles (SPSR) Score
Time frame: Baseline (DB) to 12 Months of DB Phase
Change From Baseline in the Treatment Satisfaction Questionnaire for Medication (TSQM-9) Total Score
Time frame: Baseline (DB) to 12 Months of DB Phase
Change From Baseline in the Simpson-Angus Rating Scale (SAS) Total Score
Time frame: Baseline (DB) to 12 Months of DB Phase
Number of Participants With Symptoms of Akathisia Assessed Using Barnes Akathisia Rating Scale (BARS) Score
Time frame: Up to 12 Months of DB Phase
Change From Baseline in the Abnormal Involuntary Movement Scale (AIMS) Total Score
Time frame: Baseline (DB) to 12 Months of DB Phase
Number of Participants Based on Columbia Suicide Severity Rating Scale (C-SSRS) Total Score
Time frame: Baseline and endpoint (12 Months of DB Phase)
Number of Participants With Treatment-emergent Abnormal Electrocardiogram (ECG) Values During DB Phase
Time frame: Baseline (DB) to 12 Months of DB Phase
Change From Baseline in the Body Mass Index (BMI) During DB Phase
Time frame: Baseline (DB) to 12 Months of DB Phase
Change From Baseline in the Waist Circumference During DB Phase
Time frame: Baseline (DB) to 12 Months of DB Phase
Change From Baseline in the Body Weight During DB Phase
Time frame: Baseline (DB) to 12 Months of DB Phase
Change From Baseline in the Vital Signs (Pulse Rate) During DB Phase
Time frame: Baseline (DB) to 12 Months of DB Phase
Change From Baseline in the Vital Signs (Systolic Blood Pressure [SBP] and Diastolic Blood Pressure [DBP]) During DB Phase
Time frame: Baseline (DB) to 12 Months of DB Phase
Change From Baseline in Positive and Syndrome Scale (PANSS) Subscales Score During DB Phase
Time frame: Baseline (DB) to 12 Months of DB Phase
Number of Participants With Treatment-emergent Clinically Significant Abnormal Laboratory Values in Chemistry During DB Phase
Time frame: Up to 12 Months of DB Phase
Number of Participants With Treatment-emergent Clinically Significant Abnormal Laboratory Values in Hematology During DB Phase
Time frame: Up to 12 Months of DB Phase
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Apr 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 42623271Guirguis M, Knight RK, Sanga P, Han J, Galderisi S. Weight and metabolic changes in patients with schizophrenia treated with paliperidone palmitate 6-month formulation versus paliperidone palmitate 3-month formulation: a post-hoc analysis. Int J Neuropsychopharmacol. 2026 Sep 1;29(9):pyag042. doi: 10.1093/ijnp/pyag042.
- Derived from this study: PubMed 39511777Correll CU, Johnston KL, Turkoz I, Kutch M, Knight RK, Doring M, Sajatovic M. Comparing two transitioning strategies to paliperidone palmitate once-every-6-months. CNS Spectr. 2024 Dec;29(6):633-639. doi: 10.1017/S1092852924000476. Epub 2024 Nov 8.
- Derived from this study: PubMed 37653768Richarz U, Han J, Bai YM, Yu-Hai Chen E, Chung YC, Jhanwar VG, Kim SW, Sulaiman AH, Knight K, Gopal S. Efficacy and safety of paliperidone palmitate 6-monthly long-acting injectable in reduction of relapses in patients with schizophrenia: An Asian subgroup analysis of phase 3, randomized study. Medicine (Baltimore). 2023 Aug 25;102(34):e34623. doi: 10.1097/MD.0000000000034623.
- Derived from this study: PubMed 37480362Najarian D, Turkoz I, Knight RK, Galderisi S, Lamaison HF, Zalitacz P, Aravind S, Richarz U. Long-Term Efficacy and Safety of Paliperidone 6-Month Formulation: An Open-Label 2-Year Extension of a 1-Year Double-Blind Study in Adult Participants With Schizophrenia. Int J Neuropsychopharmacol. 2023 Aug 29;26(8):537-544. doi: 10.1093/ijnp/pyad028.
- Derived from this study: PubMed 34791283Najarian D, Sanga P, Wang S, Lim P, Singh A, Robertson MJ, Cohen K, Schotte A, Milz R, Venkatasubramanian R, T'Jollyn H, Walling DP, Galderisi S, Gopal S. A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia. Int J Neuropsychopharmacol. 2022 Mar 17;25(3):238-251. doi: 10.1093/ijnp/pyab071.
Related trials for Schizophrenia
RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia
Schizophrenia
Active, not recruitingPhase 2/3
Low Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy
Suicidal Ideation, Major Depressive Disorder
RecruitingObservational study
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
Schizophrenia
Not yet recruitingPhase 1
A Study to Assess the Safety, Tolerability and Pharmacokinetics of XEP527 in Patients With Stable Schizophrenia
Schizophrenia
Not yet recruitingPhase 1
Phase I Trial of HHK101 in Patients With Schizophrenia
Schizophrenia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Janssen Research & Development, LLC Clinical Trial study director
Janssen Research & Development, LLC
138 sites in 21 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing PP6M, PP3M 350 mg eq. and PP3M 525 mg eq. in people with Schizophrenia, run by Janssen Research & Development, LLC at 138 sites in 21 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 138 sites in United States, Russia, Poland, Ukraine, India and 16 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 9 Dec 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time to Relapse During the Double-Blind (DB) Phase (time frame: Up to 12 months of DB Phase). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03345342, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Apr 2025.